Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dr. Oregonin is a biotechnology company focused on the development and commercialization of bioactive compounds derived from natural sources, specifically the diarylheptanoid oregonin found in Alnus (alder) species. The company leverages proprietary extraction and purification technologies to produce high-purity oregonin for use in nutraceuticals, cosmeceuticals, and potentially pharmaceutical applications. Their research emphasizes the anti-inflammatory, antioxidant, and metabolic benefits of oregonin, targeting conditions related to chronic inflammation and oxidative damage. Dr. Oregonin aims to bridge the gap between traditional herbal knowledge and modern evidence-based medicine through rigorous scientific validation of their botanical extracts.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Dr. Oregonin.